title: The PREHAMI (PREsillion™ in high-risk acute myocardial infarction) registry: in-hospital and long-term outcomes.
abstract: OBJECTIVE
  To evaluate the efficacy of the new Cobalt-Chromium (Co-Cr) Presillion™ stent for the treatment of high-risk acute myocardial infarction (MI) patients.
  
  
  BACKGROUND
  Percutaneous coronary intervention (PCI) with stent represents the gold standard treatment for acute MI.
  
  
  RESULTS
  We enrolled patients with high-risk acute MI (either ST-segment elevation MI or non-ST-segment elevation MI) treated with PCI using a new Co-Cr bare metal stent with closed cells design and limited balloon compliance. We considered high-risk features as one of the following: age ≥ 70 years, ejection fraction ≤ 35%, glomerular filtration rate ≤ 60 mL/min, diabetes mellitus, rescue PCI, or chronic atrial fibrillation or other conditions requiring long-term oral anticoagulation therapy. Primary outcome of the study was rate of major adverse cardiac events (MACE) defined as all-cause death, new MI, and target-vessel revascularization. A total of 129 consecutive patients were enrolled (69 ± 11 years, 74% men): 71 (55%) patients with ST-segment elevation MI and 58 (45%) patients with non-ST-segment elevation MI. A total of 153 vessels (169 lesions and 179 stents) were treated. The device success rate was high (98.8%). In-hospital MACE rate was 5.4% mainly because of death associated with the acute MI. At 1-year follow-up, the MACE rate was 17.3%, with 11% all-cause death (7.9% of cardiac origin), 0.6% of stent thrombosis, and 4.6% target-vessel revascularization.
  
  
  CONCLUSIONS
  The use of the Co-Cr Presillion stent in patients with high-risk acute MI treated invasively seems to be safe and efficacious with optimal deliverability and good long-term outcomes and represents a good option in the treatment of these patients.
authors.affiliation: Cardiologia, Policlinico Casilino, ASL RMB, Rome, Italy. alessandro.sciahbasi@fastwebnet.it
authors.forename: Alessandro
authors.initials: A
authors.lastname: Sciahbasi
authors.forename: Gianluca
authors.initials: G
authors.lastname: Pendenza
authors.forename: Enrico
authors.initials: E
authors.lastname: Romagnoli
authors.forename: Francesco
authors.initials: F
authors.lastname: Summaria
authors.forename: Roberto
authors.initials: R
authors.lastname: Patrizi
authors.forename: Valerio
authors.initials: V
authors.lastname: Lucci
authors.forename: Maria Benedetta
authors.initials: MB
authors.lastname: Giannico
authors.forename: Maria
authors.initials: M
authors.lastname: Penco
authors.forename: Ernesto
authors.initials: E
authors.lastname: Lioy
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D002858:Chromium Alloys; D017023:Coronary Angiography; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007297:Inpatients; D007558:Italy; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D011446:Prospective Studies; D011474:Prosthesis Design; D012008:Recurrence; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002858:Chromium Alloys